Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:6166 |
| Name | prostatic urethra urothelial carcinoma |
| Definition | |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer organ system cancer urinary system cancer urethra cancer male urethral cancer prostatic urethral cancer prostatic urethra urothelial carcinoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT00794950 | Phase II | Sunitinib | Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma | Completed | USA | 0 |
| NCT01688999 | Phase II | Cabozantinib | Cabozantinib for Advanced Urothelial Cancer | Completed | USA | 0 |
| NCT03106610 | Phase I | Nivolumab | Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy | Terminated | USA | 0 |
| NCT03549715 | Phase Ib/II | Cisplatin + Doxorubicin + Durvalumab + Methotrexate + Tremelimumab + Vinblastine Cisplatin + Doxorubicin + Durvalumab + Methotrexate + Vinblastine | NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma (NEMIO) | Active, not recruiting | FRA | 0 |
| NCT04506554 | Phase II | Cisplatin + Doxorubicin + Methotrexate + Nivolumab + Vinblastine | A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer | Active, not recruiting | USA | 0 |